Monthly Archives: April 2016

Yen Surge Continues Unabated

The Japanese yen surged for the fifth-straight day on Thursday, strengthening by as much as 1.7% to 107.92 against the dollar and hitting the strongest level since October 19, 2014 — right before the Bank of Japan shocked the markets by boosting its quantitative-easing program. It fell overnight into Friday after Japanese Finance Minister Taro…

Gold Sector: Macrocosm Updated

We do in depth analysis on a weekly basis (and every day in-week) because there is no substitute for working to be right with the market’s evolving situation as opposed to making bias or ego stoked calls in hopes of being right. The current situation has seen some calling ‘bullish’ on the stock market despite a still intact bear…

Biotechnology Sentiment At Multi-Year Extremes. What Should Inves

The biotechnology sector has experienced a big rally in recent weeks. Uncoincidentally, the rally started right at major support, as seen on the first chart (lower purple line which was tested in March). The chart also shows that the first resistance line is reached (horizontal purple line), while major resistance is just 10% above today’s price (descending…

Top 5 Growth Stocks Under $10

Making big gains on a small budget may sound too good to be true. But the idea is worth pursuing, especially with the help of low-priced stocks. Of course, what may be a low price for one may not be for another. So here we’re considering stocks that are priced low enough for everyone, i.e….

Morning Call For April 8, 2016

OVERNIGHT MARKETS AND NEWS Jun E-mini S&Ps (ESM16 +0.53%) are up +0.58% and European stocks are up +1.01%. A +3.46% rally in crude oil to a 1-week high has boosted energy producing stocks and pulled the overall market higher, while comments made last night from Fed Chair Yellen reinforce her previous comments that the Fed will…

AstraZeneca, Eli Lilly To Continue Trial For People With Early Al

AstraZeneca (AZN) and Eli Lilly (LLY) announced that AMARANTH, a Phase II/III study of AZD3293, an oral beta secretase cleaving enzyme inhibitor currently in development as a potential treatment for early Alzheimer’s disease, will continue into Phase III of the Phase II/III seamless trial. The AMARANTH independent data monitoring committee recommended the study continue without…